Subjective Complaints as Main Reason for Biosimilar...

  • Main
  • 2017 / 10
  • Subjective Complaints as Main Reason for Biosimilar...
Arthritis & Rheumatology 2017 / 10

Subjective Complaints as Main Reason for Biosimilar Discontinuation after Open Label Transitioning from Originator to Biosimilar Infliximab

Tweehuysen, Lieke, van den Bemt, Bart J F, van Ingen, Iris L, de Jong, Alphons J L, van der Laan, Willemijn H, van den Hoogen, Frank H J, den Broeder, Alfons A
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Arthritis & Rheumatology
DOI:
10.1002/art.40324
Date:
October, 2017
File:
PDF, 763 KB
english, 2017
Conversion to is in progress
Conversion to is failed